The global organ-tumor-on-a-chip market was valued at $5,937.27 thousand in 2020, and is projected to reach $117,471.41 thousand by 2030, registering a CAGR of 34.3% from 2021 to 2030.
Organ-tumor-on-a-chip is a miniature cell culture device that simulates tumor cell tissue structure and functional units in vitro. Tumor chips can ideally reproduce specific key aspects of the tumor microenvironment, such as biochemical gradients and niche factors, dynamic cell-cell and cell-matrix interactions, and complex tissue structure comprised of tumor and stromal cells. The capability of microfluidic devices to integrate all the necessary components in a less than 1-inch silicon chip along with the advances in micro electromechanical systems (MEMS) led to highly efficient lab-on-a-chip devices (LOC).
Tumor-on-a-chip is a miniature cell culture device that simulates tumor cell tissue structure and functional units in vitro. Tumor-on-a-chip can be used to simulate tumor growth and expansion, angiogenesis, and progression from early to advanced lesions involving epithelial-mesenchymal transition (EMT), tumor cell invasion and metastasis. organ-on-a-chip systems are based on the use of microfluidics to construct tissue models Other unique features of a microfluidic platform such as its perfect length scale fitting at cellular and tissue levels as well as very small quantity of required agents made them an excellent choice for biological applications. The emerging tumor-on-a-chip platforms integrating 3D cell culture, microfluidic technology, and tissue engineering have successfully mimicked the pivotal structural and functional characteristics of the in vivo tumor microenvironment.
Factors that drive the organ-tumor-on-a-chip market include a rise in the prevalence of cancer and the rising demand of personalized medicine globally. Personalized medicine has a strong impact on the healthcare industry leading to the increase of personalized medicine worldwide, especially in cancer treatments. Furthermore, cheaper availability of organ-tumor-on-a-chip can boost market growth. While, the complex nature and less user friendly to handle can hamper growth of organ-tumor-on-a- chip market over the forecast period.
Therefore, new biomarkers and simple and efficient test methods such as a smaller sample and miniaturization, protein microarray technology does have great potential in cancer diagnosis. However, complexity of the protein microarray (chip) during the production and quantification is expected to impede the growth of protein chip market over the forecast period.
The market is expected to witness moderate growth during the forecast period, owing to technological advancement in organ-tumor-on-a-chips.
The organ-tumor-on-a-chip market is segmented on the basis of type and region.
By type, it is categorized into lung tumor-on-a-chip, bone marrow tumor-on-a-chip, brain tumor-on-a-chip, breast tumor-on-a-chip, urinary system tumor-on-a-chip, intestine tumor-on-a-chip, and liver tumor-on-a-chip. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.
The prominent players in the market have adopted various strategies for increasing their market share. These include expansion of their geographical presence through acquisitions and developing long acting and effective products with lower adverse effects. Major players operating in the organ-tumor-on-a-chip market include Axosim Technologies LLC, Beonchip S. L., BioIVT LLC, Emulate Inc., InSphero AG, Mimetas B.V., Nortis, Inc., and Organovo Holdings, Inc.
North America accounted for the highest revenue share in the organ-tumor-on-a-chip market in 2020 and is expected to dominate over the forecast period. , Asia-Pacific is expected to grow at a highest CAGR during the forecast period.
Organ-tumor-on-a-chip is a miniature cell culture device that simulates tumor cell tissue structure and functional units in vitro. Tumor chips can ideally reproduce specific key aspects of the tumor microenvironment, such as biochemical gradients and niche factors, dynamic cell-cell and cell-matrix interactions, and complex tissue structure comprised of tumor and stromal cells. The capability of microfluidic devices to integrate all the necessary components in a less than 1-inch silicon chip along with the advances in micro electromechanical systems (MEMS) led to highly efficient lab-on-a-chip devices (LOC).
Tumor-on-a-chip is a miniature cell culture device that simulates tumor cell tissue structure and functional units in vitro. Tumor-on-a-chip can be used to simulate tumor growth and expansion, angiogenesis, and progression from early to advanced lesions involving epithelial-mesenchymal transition (EMT), tumor cell invasion and metastasis. organ-on-a-chip systems are based on the use of microfluidics to construct tissue models Other unique features of a microfluidic platform such as its perfect length scale fitting at cellular and tissue levels as well as very small quantity of required agents made them an excellent choice for biological applications. The emerging tumor-on-a-chip platforms integrating 3D cell culture, microfluidic technology, and tissue engineering have successfully mimicked the pivotal structural and functional characteristics of the in vivo tumor microenvironment.
Factors that drive the organ-tumor-on-a-chip market include a rise in the prevalence of cancer and the rising demand of personalized medicine globally. Personalized medicine has a strong impact on the healthcare industry leading to the increase of personalized medicine worldwide, especially in cancer treatments. Furthermore, cheaper availability of organ-tumor-on-a-chip can boost market growth. While, the complex nature and less user friendly to handle can hamper growth of organ-tumor-on-a- chip market over the forecast period.
Therefore, new biomarkers and simple and efficient test methods such as a smaller sample and miniaturization, protein microarray technology does have great potential in cancer diagnosis. However, complexity of the protein microarray (chip) during the production and quantification is expected to impede the growth of protein chip market over the forecast period.
The market is expected to witness moderate growth during the forecast period, owing to technological advancement in organ-tumor-on-a-chips.
The organ-tumor-on-a-chip market is segmented on the basis of type and region.
By type, it is categorized into lung tumor-on-a-chip, bone marrow tumor-on-a-chip, brain tumor-on-a-chip, breast tumor-on-a-chip, urinary system tumor-on-a-chip, intestine tumor-on-a-chip, and liver tumor-on-a-chip. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.
The prominent players in the market have adopted various strategies for increasing their market share. These include expansion of their geographical presence through acquisitions and developing long acting and effective products with lower adverse effects. Major players operating in the organ-tumor-on-a-chip market include Axosim Technologies LLC, Beonchip S. L., BioIVT LLC, Emulate Inc., InSphero AG, Mimetas B.V., Nortis, Inc., and Organovo Holdings, Inc.
North America accounted for the highest revenue share in the organ-tumor-on-a-chip market in 2020 and is expected to dominate over the forecast period. , Asia-Pacific is expected to grow at a highest CAGR during the forecast period.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global organ-tumor-on-a-chip market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of protein chips used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Type
- Lung Tumor-on-a-chip
- Bone Marrow Tumor-on-a-chip
- Brain Tumor-on-a-chip
- Breast Tumor-on-a-chip
- Urinary System Tumor-on-a-chip
- Intestine Tumor-on-a-chip
- Liver Tumor-on-a-chip
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Axosim Technologies LLC
- Beonchip S. L.
- BioIVT LLC
- Emulate Inc.
- InSphero AG
- Mimetas B.V.
- Nortis, Inc.
- Organovo Holdings, Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: ORGAN-TUMOR-ON-A-CHIP MARKET, BY TYPE
CHAPTER 5: ORGAN-TUMOR-ON-A-CHIP, BY REGION
CHAPTER 6: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Axosim Technologies LLC
- Beonchip S. L
- BioIVT LLC
- Emulate Inc.
- InSphero AG
- Mimetas B.V.
- Nortis Inc.
- Organovo Holdings Inc
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | November 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 5937.27 thousand |
| Forecasted Market Value ( USD | $ 117471.41 thousand |
| Compound Annual Growth Rate | 34.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
